+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hematological Malignancies Market by Disease Type, Treatment Type, Therapy Class, Line of Therapy, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Hematological Malignancies Market by Disease Type, Treatment Type, Therapy Class, Line of Therapy, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Hematological Malignancies Market by Disease Type, Treatment Type, Therapy Class, Line of Therapy, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887514
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The hematological malignancies market is rapidly transforming, driven by scientific advances and evolving regulatory frameworks. For business leaders, understanding market dynamics, emerging technologies, and global growth patterns is critical for effective portfolio management and strategic positioning.

Market Snapshot: Hematological Malignancies Market Overview

The Hematological Malignancies Market grew from USD 16.84 billion in 2024 to USD 18.58 billion in 2025. It is expected to continue growing at a CAGR of 9.95%, reaching USD 29.76 billion by 2030. Market expansion is anchored by the uptake of targeted therapies, real-world data integration, and rising investment in next-generation treatments. Accelerated regulatory pathways and adaptive reimbursement models have created fertile ground for innovation, collaborative endeavors, and value-based care initiatives within the sector.

Scope & Segmentation

This report delivers comprehensive coverage through the following segmentation layers, designed to equip decision-makers with actionable insights:

  • Disease Types: Leukemia (Acute Lymphoblastic, Acute Myeloid, Chronic Lymphocytic, Chronic Myeloid), Lymphoma (Hodgkin: Classical, Nodular Lymphocyte-Predominant; Non-Hodgkin: B-Cell, T-Cell), Multiple Myeloma, Myelodysplastic Syndromes (Refractory Anemia variants), and Myeloproliferative Neoplasms (Essential Thrombocythemia, Myelofibrosis, Polycythemia Vera).
  • Treatment Types: Chemotherapy, Immunotherapy (CAR-T Cell Therapy, Checkpoint Inhibitors), Stem Cell Transplantation (Allogeneic, Autologous), Targeted Therapy (Immunomodulators, Monoclonal Antibodies, Proteasome Inhibitors, Tyrosine Kinase Inhibitors).
  • Therapy Classes: Cellular Therapies (CAR-T, Dendritic Cell Vaccines), Immunomodulatory Drugs (Pomalidomide, Thalidomide), Monoclonal Antibodies (Anti-CD20, Anti-CD38), Proteasome Inhibitors (Bortezomib, Carfilzomib), Small Molecule Inhibitors (Tyrosine Kinase Inhibitors, Venetoclax).
  • Line of Therapy: First-Line, Maintenance Therapy, Second-Line, Third-Line and Beyond.
  • End Users: Ambulatory Care Centers, Hospitals, Research Institutes, Specialty Clinics.
  • Distribution Channels: Direct Purchase, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies.
  • Patient Age Groups: Adult, Geriatric, Pediatric.
  • Regions: Americas (US: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (including UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Companies Profiled: Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., F. Hoffmann-La Roche AG, Novartis AG, Gilead Sciences, Inc., Pfizer Inc., Amgen Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.

Key Takeaways for Senior Decision-Makers

  • Adoption of cellular and targeted therapies continues to reshape hematologic cancer care, enhancing treatment outcomes and enabling more precise patient stratification.
  • Strategic collaborations between biotechnology and large pharmaceutical firms are unlocking co-development opportunities, especially in bispecific antibodies and companion diagnostics.
  • Real-world evidence and digital health solutions are being used to refine clinical trial design, monitor outcomes, and optimize market access strategies.
  • Regional adoption rates vary significantly, with mature markets benefiting from established reimbursement systems and emerging regions seeing increased uptake through localization initiatives.
  • Supply chain and distribution strategies require agility as evolving tariff scenarios and local policy changes influence procurement and access pathways.
  • Portfolio diversification—balancing novel therapeutics with established assets—remains essential for mitigating development and pricing risks.

Anticipating Tariff Impact in the US Market

Impending tariff increases on pharmaceutical imports in the United States are poised to influence supply chain decisions and pricing structures. Manufacturers may increase local production or revise sourcing models to offset cost pressures. Payers and providers could experience shifts in therapy acquisition expenses, prompting fresh negotiations and the expansion of value-driven contracts. Collaborative agreements between domestic firms and manufacturing partners may rise, as industry players pursue stability amid evolving policy environments. Timely regulatory pathways and cost-mitigating strategies will be critical for maintaining patient access to imported biologics and advanced treatments.

Methodology & Data Sources

This analysis synthesizes primary interviews with KOLs, executives, and reimbursement experts across key markets, combined with secondary research from peer-reviewed publications, regulatory sources, and company disclosures. Quantitative findings were rigorously cross-validated using a triangulation process to ensure coherence and reliability. Expert panels contributed further guidance on pipeline evolution and regional market dynamics.

Why This Report Matters

  • Enables C-level executives to identify emerging opportunities and proactively address challenges in the hematological malignancies space.
  • Delivers detailed segmentation and technology trends, supporting research prioritization and informed investment decisions.
  • Offers a robust foundation for strategic planning, partnership evaluation, and market entry strategies amid changing regulatory and competitive landscapes.

Conclusion

This report provides senior leaders with focused insights and strategic clarity into the rapidly evolving hematological malignancies market. Informed decisions based on these findings can drive sustainable growth, successful partnerships, and innovation in patient care solutions.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hematological Malignancies Market, by Disease Type
8.1. Introduction
8.2. Leukemia
8.2.1. Acute Lymphoblastic Leukemia
8.2.2. Acute Myeloid Leukemia
8.2.3. Chronic Lymphocytic Leukemia
8.2.4. Chronic Myeloid Leukemia
8.3. Lymphoma
8.3.1. Hodgkin Lymphoma
8.3.1.1. Classical
8.3.1.2. Nodular Lymphocyte-Predominant
8.3.2. Non-Hodgkin Lymphoma
8.3.2.1. B-Cell
8.3.2.2. T-Cell
8.4. Multiple Myeloma
8.5. Myelodysplastic Syndromes
8.5.1. Refractory Anemia
8.5.2. Refractory Anemia With Excess Blasts
8.5.3. Refractory Anemia With Ring Sideroblasts
8.5.4. Refractory Cytopenia With Multilineage Dysplasia
8.6. Myeloproliferative Neoplasms
8.6.1. Essential Thrombocythemia
8.6.2. Myelofibrosis
8.6.3. Polycythemia Vera
9. Hematological Malignancies Market, by Treatment Type
9.1. Introduction
9.2. Chemotherapy
9.3. Immunotherapy
9.3.1. CAR-T Cell Therapy
9.3.2. Checkpoint Inhibitors
9.4. Stem Cell Transplantation
9.4.1. Allogeneic
9.4.2. Autologous
9.5. Targeted Therapy
9.5.1. Immunomodulators
9.5.1.1. Lenalidomide
9.5.1.2. Thalidomide
9.5.2. Monoclonal Antibodies
9.5.2.1. Anti-CD20
9.5.2.2. Anti-CD38
9.5.3. Proteasome Inhibitors
9.5.3.1. Bortezomib
9.5.3.2. Carfilzomib
9.5.4. Tyrosine Kinase Inhibitors
9.5.4.1. BCR-ABL Inhibitors
9.5.4.2. BTK Inhibitors
10. Hematological Malignancies Market, by Therapy Class
10.1. Introduction
10.2. Cellular Therapies
10.2.1. CAR-T Cell Therapy
10.2.2. Dendritic Cell Vaccines
10.3. Immunomodulatory Drugs
10.3.1. Pomalidomide
10.3.2. Thalidomide
10.4. Monoclonal Antibodies
10.4.1. Anti-CD20
10.4.2. Anti-CD38
10.5. Proteasome Inhibitors
10.5.1. Bortezomib
10.5.2. Carfilzomib
10.6. Small Molecule Inhibitors
10.6.1. Tyrosine Kinase Inhibitors
10.6.2. Venetoclax
11. Hematological Malignancies Market, by Line of Therapy
11.1. Introduction
11.2. First-Line
11.3. Maintenance Therapy
11.4. Second-Line
11.5. Third-Line and Beyond
12. Hematological Malignancies Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Hospitals
12.4. Research Institutes
12.5. Specialty Clinics
13. Hematological Malignancies Market, by Distribution Channel
13.1. Introduction
13.2. Direct Purchase
13.3. Hospital Pharmacies
13.4. Online Pharmacies
13.5. Retail Pharmacies
14. Hematological Malignancies Market, by Patient Age Group
14.1. Introduction
14.2. Adult
14.3. Geriatric
14.4. Pediatric
15. Americas Hematological Malignancies Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Hematological Malignancies Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Hematological Malignancies Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Bristol-Myers Squibb Company
18.3.2. Johnson & Johnson
18.3.3. AbbVie Inc.
18.3.4. F. Hoffmann-La Roche AG
18.3.5. Novartis AG
18.3.6. Gilead Sciences, Inc.
18.3.7. Pfizer Inc.
18.3.8. Amgen Inc.
18.3.9. Sanofi S.A.
18.3.10. Takeda Pharmaceutical Company Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. HEMATOLOGICAL MALIGNANCIES MARKET MULTI-CURRENCY
FIGURE 2. HEMATOLOGICAL MALIGNANCIES MARKET MULTI-LANGUAGE
FIGURE 3. HEMATOLOGICAL MALIGNANCIES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. HEMATOLOGICAL MALIGNANCIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. HEMATOLOGICAL MALIGNANCIES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HEMATOLOGICAL MALIGNANCIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CLASSICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NODULAR LYMPHOCYTE-PREDOMINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY B-CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY T-CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH EXCESS BLASTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH RING SIDEROBLASTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ESSENTIAL THROMBOCYTHEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOFIBROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POLYCYTHEMIA VERA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BTK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY VENETOCLAX, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THIRD-LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 155. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 156. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 157. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 158. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 159. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 160. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2030 (USD MILLION)
TABLE 161. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2030 (USD MILLION)
TABLE 162. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 164. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 165. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 166. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 167. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 171. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2030 (USD MILLION)
TABLE 172. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 173. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 174. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 177. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 181. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 182. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 183. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 184. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 185. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2030 (USD MILLION)
TABLE 186. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2030 (USD MILLION)
TABLE 187. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 189. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 190. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 191. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 192. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 193. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 196. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2030 (USD MILLION)
TABLE 197. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 198. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 199. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 201. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 202. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 206. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 207. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 208. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 209. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 210. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2030 (USD MILLION)
TABLE 211. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2030 (USD MILLION)
TABLE 212. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 214. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 215. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 216. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 217. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 218. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 219. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 221. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2030 (USD MILLION)
TABLE 222. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 223. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 224. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 225. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 227. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 231. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 232. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 233. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 234. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 235. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2030 (USD MILLION)
TABLE 236. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2030 (USD MILLION)
TABLE 237. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 239. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 240. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 241. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 242. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 243. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 246. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2030 (USD MILLION)
TABLE 247. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 248. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 249. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 252. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2030 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2030 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 286. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2030 (USD MILLION)
TABLE 288. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 290. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 292. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 294. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 296. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2030 (USD MILLION)
TABLE 298. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2030 (USD MILLION

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hematological Malignancies market report include:
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • AbbVie Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 18.58 Billion
Forecasted Market Value ( USD ) by 2030 $ 29.76 Billion
Compound Annual Growth Rate9.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hematological Malignancies - Global Strategic Business Report - Product Image

Hematological Malignancies - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Hematological Malignancies Disease Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Hematological Malignancies Disease Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 110 Pages
  • Global
From
Drugs and Diagnostics for Hematological Disorders: Global Markets - Product Image

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • Report
  • 133 Pages
  • Global
From
Hematologic Malignancies Market Size, Share & Trends Analysis Report By Disease (Leukemia, Lymphoma), By Therapy (Chemotherapy, Immunotherapy), By End Use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Hematologic Malignancies Market Size, Share & Trends Analysis Report By Disease (Leukemia, Lymphoma), By Therapy (Chemotherapy, Immunotherapy), By End Use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Hematologic Malignancies Market Report by Type, Therapy, End User, and Region 2024-2032 - Product Image

Hematologic Malignancies Market Report by Type, Therapy, End User, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From

About the Hematological Malignancies Drug Market

The Hematological Malignancies Drug market is a subset of the pharmaceutical industry that focuses on the development and production of drugs used to treat leukemia and other blood-related cancers. These drugs are used to treat a variety of conditions, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The drugs are typically administered intravenously or orally, and may be used in combination with other treatments such as chemotherapy or radiation therapy. The Hematological Malignancies Drug market is highly competitive, with many companies vying for market share. Some of the major players in the market include Novartis, Celgene, Pfizer, Bristol-Myers Squibb, and Merck. Other companies in the market include AbbVie, AstraZeneca, Johnson & Johnson, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.